GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Shiller PE Ratio

Zeo ScientifiX (Zeo ScientifiX) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zeo ScientifiX Shiller PE Ratio Historical Data

The historical data trend for Zeo ScientifiX's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Shiller PE Ratio Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zeo ScientifiX's Shiller PE Ratio

For the Biotechnology subindustry, Zeo ScientifiX's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Shiller PE Ratio falls into.



Zeo ScientifiX Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zeo ScientifiX's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, Zeo ScientifiX's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.001/129.4194*129.4194
=-0.001

Current CPI (Jan. 2024) = 129.4194.

Zeo ScientifiX Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -0.008 100.023 -0.010
201407 -0.008 100.520 -0.010
201410 -1.937 100.176 -2.502
201501 -0.019 98.604 -0.025
201504 -0.017 99.824 -0.022
201507 -0.480 100.691 -0.617
201510 -1.484 100.346 -1.914
201601 -0.643 99.957 -0.833
201604 -0.593 100.947 -0.760
201607 -0.449 101.524 -0.572
201610 0.000 101.988 0.000
201701 -8.000 102.456 -10.105
201704 -6.000 103.167 -7.527
201707 -2.000 103.278 -2.506
201710 0.000 104.070 0.000
201801 -0.237 104.578 -0.293
201804 -4.000 105.708 -4.897
201807 -0.151 106.324 -0.184
201810 -0.195 106.695 -0.237
201901 -0.111 106.200 -0.135
201904 -0.186 107.818 -0.223
201907 -0.147 108.250 -0.176
201910 -0.299 108.577 -0.356
202001 -0.276 108.841 -0.328
202004 -0.525 108.173 -0.628
202007 -2.000 109.318 -2.368
202010 -2.000 109.861 -2.356
202101 -2.000 110.364 -2.345
202104 -0.425 112.673 -0.488
202107 -0.256 115.183 -0.288
202110 0.000 116.696 0.000
202201 -0.320 118.619 -0.349
202204 -0.270 121.978 -0.286
202207 -0.502 125.002 -0.520
202210 -0.408 125.734 -0.420
202301 -0.002 126.223 -0.002
202304 -0.274 127.992 -0.277
202307 -0.228 128.974 -0.229
202310 -0.150 129.810 -0.150
202401 -0.001 129.419 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zeo ScientifiX  (OTCPK:ZEOX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zeo ScientifiX Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140